BAFISONTAMAB

UNII:	G86X5QQ7M5
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	BAFISONTAMAB
GSRS Full Record:	G86X5QQ7M5 i

2437210-79-0
ANTI-EGFR/ANTI-C-MET BISPECIFIC ANTIBODY EMB-01
BAFISONTAMAB [USAN]
Bafisontamab
Bafisontamab [WHO-DD]
EMB-01
EMB01
FIT-013A
Immunoglobulin G1, bispecific, anti-(human hepatocyte growth factor receptor c-Met) (human κ-chain) fusion protein with immunoglobulin G1 anti-(human epidermal growth factor receptor) (human γ1-chain), disulfide with immunoglobulin G1 anti-(human hepatocyte growth factor receptor c-Met) human γ1-chain N-terminal fragment and immunoglobulin G1 anti-(human epidermal growth factor receptor) human κ-chain, dimer
Immunoglobulin G1-kappa-Fab, anti-[Homo sapiens MET (MET proto-oncogene receptor tyrosine kinase, HGFR, RCCP2, DFNB97)] and anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], Homo sapiens and humanized monoclonal antibody, bispecific; kappa light chain and gamma1 heavy chain Homo sapiens and humanized anti-MET and anti-EGFR (V-KAPPA-CKAPPA-VH-CH1-h-CH2-CH3) (1-663) [V-KAPPA Homo sapiens anti-MET (Homo sapiens IGKV1-12*01 (96.8%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1-107) -Homo sapiens IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108-214) -VH humanized anti-EGFR (Homo sapiens IGHV4-61*01 (89.9%) -(IGHD) -IGHJ3*02 (100%), CDR-IMGT [10.7.11] (240-249.267-273.312-322)) (215-333) -Homo sapiens IGHG1*03v G1m3>G1m17, nG1m1 (CH1 R120>K (430) (334-431), hinge 1-15 (432-446), CH2 (447-556), CH3 E12 (572), M14 (574) (557-661), CHS (662-663)) (334-663)], (436-214''')-disulfide with Fab G1-kappa anti-MET and anti-EGFR Homo sapiens [VH (CH1-hinge) gamma1 heavy chain (1''-220'') anti-MET (Homo sapiens IGHV1-18*01 (96.9%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.10] (26-33.51-58.97-106)) (1''-117'') -Homo sapiens IGHG1*01, G1m17 (CH1 K120 (214) (118''-215''), hinge 1-5 (216''-220'') (118''-220'')], (214''-220''')-disulfide with kappa light chain Homo sapiens anti-EGFR (1'''-214''') [V-KAPPA (Homo sapiens IGKV1-33*01 (95.8%) -IGKJ4*01 (91.7%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'''-107''') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'''-214''')]; dimer (442-442'':445-445'')-bisdisulfide, produced in a Chinese hamster ovary (CHO)-K1 cell line, glycoform alfa
bafisontamab [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

BAFISONTAMAB

Synonyms and Mappings

Resources